Related Experiment Video
Updated: Oct 13, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Obstructive sleep apnea therapy for cardiovascular risk reduction-Time for a rethink?
Hasthi U Dissanayake1, Juliana T Colpani2, Kate Sutherland1
1Sleep Research Group, Charles Perkins Centre & Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
Obstructive sleep apnea (OSA) treatment with mandibular advancement devices (MADs) offers better patient adherence than CPAP. This improved usage may lead to comparable cardiovascular benefits and reduced risks.
Area of Science:
- Cardiology
- Sleep Medicine
- Medical Devices
Background:
- Obstructive sleep apnea (OSA) is common and linked to cardiovascular and metabolic diseases.
- Continuous positive airway pressure (CPAP) is the standard OSA therapy but has low patient adherence.
- Low CPAP usage may hinder its effectiveness in reducing cardiovascular risk.
Purpose of the Study:
- To review the cardiovascular impact of OSA.
- To discuss CPAP limitations in OSA management.
- To explore the potential of mandibular advancement devices (MADs) for cardiovascular risk reduction.
Main Methods:
- Literature review summarizing OSA's cardiovascular effects.
- Analysis of CPAP adherence and effectiveness.
- Evaluation of MADs as an alternative OSA therapy.
Main Results:
- MADs are preferred by patients over CPAP due to better tolerance.
- Despite lower efficacy in event reduction, MADs' higher usage yields comparable quality-of-life and blood pressure improvements.
- MADs present a viable option for OSA management and cardiovascular risk mitigation.
Conclusions:
- Patient adherence is crucial for effective OSA treatment.
- MADs offer a promising alternative to CPAP, improving adherence and cardiovascular outcomes.
- Further research should focus on MADs' long-term impact on cardiovascular health.
More Related Videos
05:34Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders
Published on: August 18, 2023
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...